Qiagen N.V.

NYSE:QGEN

Medical - Diagnostics & Research

Healthcare
$49.56 -0.96%

-$0.35 today

Market cap
$10.23B
Beta
0.66
P/E (TTM)
18.6
EPS (TTM)
$1.94
Dividend yield
0.69%
52W Low $32.53High $57.82

Volume 4.26M

Average 2.07M

QGEN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Qiagen N.V.NYSE: QGEN

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of $535.04M rose 0.3% year over year, behind the +3.0% change in trailing-twelve-month revenue. Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at -0.8% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 11 analysts of $2.14B (+2.3%) for the fiscal year ending Dec 2026, a slowdown from the +5.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$535.04M+8.7% QoQ
Last fiscal yearDec 2025
$2.09B+5.7% YoY
LTMJun 2026
$2.1B+3.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.3%+1.1%+0.8 pp
1 year+5.7%+2.3%-3.4 pp
3-year CAGR-0.8%+4.2%+5.0 pp
5-year CAGR+4.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
2.09B USD
Year-over-year change
+5.7%
4-year CAGR
-1.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How QGEN compares with its peers on the latest reported figures

  • QGEN's LTM Jun 2026 revenue of $2.1B is the 7th highest of the 11 companies compared; the peer median is $2.75B.
  • Its year-over-year change of +3.0% is the 6th highest of 11, against a peer median of +2.9%.
  • Over three fiscal years its annual growth of -0.8% compares with a peer median of -1.5%.
QGEN Competitors Peer median
Revenue for QGEN and competitors
Company Period LTM YoY 3-year CAGR
TMOThermo Fisher Scientific Inc.LTM Sep 2026$47.35B +8.3%-0.3%
DHRDanaher CorporationLTM Sep 2026$25.61B +5.5%-2.7%
AAgilent Technologies, Inc.LTM Jul 2026$7.37B +8.6%+0.5%
BRKRBruker CorporationLTM Jun 2026$3.5B +1.6%+10.7%
RVTYRevvity, Inc.LTM Jul 2026$2.91B +4.1%-4.8%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$2.59B +1.4%-2.7%
QGENQiagen N.V.LTM Jun 2026$2.1B +3.0%-0.8%
TECHBio-Techne CorporationLTM Sep 2026$1.23B +0.9%+2.2%
RGENRepligen CorporationLTM Jun 2026$785.1M +16.5%-2.7%
TXG10x Genomics, Inc.LTM Sep 2026$618.58M -3.6%+7.6%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$208.78M -3.3%-40.5%
Peer median (excluding QGEN) $2.75B+2.9%-1.5%

Competitors are the stored peer set for QGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.25B2.14B1.97B1.98B2.09B
Cost of Revenue800.84M756.96M731.62M1.01B798.5M
Gross Profit1.45B1.38B1.23B967.35M1.29B
Gross Margin64.4%64.7%62.8%48.9%61.8%
Research & Development189.96M189.86M198.51M193.49M187.52M
Selling, General & Admin584.47M603.95M579.17M564.36M583.67M
Operating Expenses820.74M853.1M823.75M869.64M771.19M
Depreciation & Amortization214.93M208.4M205.34M203.27M193.75M
EBITDA895.24M779.36M688.56M368.26M717.27M
EBITDA Margin39.8%36.4%35.0%18.6%34.3%
Operating Income630.08M531.46M409.94M97.71M520.31M
Operating Margin28.0%24.8%20.9%4.9%24.9%
Interest Income9.56M32.76M78.99M68.02M64.32M
Interest Expense54.48M58.36M53.41M43.84M33.26M
Other Income / Expenses(4.25M)(18.86M)19.87M23.44M(30.04M)
Income Before Tax625.83M512.6M429.81M121.15M490.27M
Pre-Tax Margin27.8%23.9%21.9%6.1%23.5%
Income Tax Expense113.23M89.39M88.51M37.56M65.39M
Net Income512.6M423.21M341.3M83.59M424.88M
Net Margin22.8%19.8%17.4%4.2%20.3%
EPS (Basic)2.522.081.670.392.04
EPS (Diluted)2.472.051.650.382.04
Weighted Avg Shares221.14M220.75M217.49M216.44M207.94M
Weighted Avg Shares (Diluted)225.07M223.23M217.49M218.48M207.94M

Qiagen N.V.

NYSE:QGEN

Intrinsic Alpha fair value

Locked

Current Price

$49.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.